Researchers showed that the test had equivalent results to a lab-based assay and has the potential for a faster turnaround time.
A lack of attractive targets, high valuations, and a more attractive IPO market contributed to a 45 percent year-over-year decline in M&A.
The company expects EPS to be between $4.02 and $4.12. On a non-GAAP basis, EPS is expected to be in the range of $4.75 and $4.85.
Sysmex accuses 13 Beckman Coulter instruments of infringing 11 claims in the patent, which covers a system analyzer and a computer program.
A court in San Diego has stated that part of the suit between Quidel and Beckman is void as a matter of law.
The classification indicates a reasonable probability that the use of, or exposure to, a recalled product will cause serious adverse health consequences or death.
Within diagnostics, Beckman Coulter saw core revenue growth in the low-single digits, while Cepheid was up in the double digits for the quarter.
The Canadian regulator gave Medical Device License approval to Beckman Coulter's DxH 900 Hematology Analyzer and its Early Sepsis Indicator.